exenatide glp 1 agonist Structures of native GLP-1, exenatide, and liraglutide. The N-terminal GLP1 receptor agonist @nejm revisión

Novel Drug Delivery Technologies Hydrogel Depot Technology Hydrogel depot technology uses injectable hydrogels to create a reservoir or depot at the injection site, allowing for sustained and controlled release of therapeutic substances over time

D.et al (2017)

GLP-1 receptor agonism is also achieved by inhibitors of dipeptidyl peptidase-4 (DPP-4), which prevent the inactivation of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), thereby prolonging their raised levels after meal ingestion

63 Albiglutide was approved for marketing in the European Union in March 2014 and in the United States in April 2014